As the number of human cases of avian influenza confirmed by the World Health Organization (WHO) rises to 281, with new cases reported in Egypt and Laos, WHO and international experts are meeting in Turkey to discuss how best to treat people who become infected with the highly pathogenic H5N1 form of the bird flu virus.
The U.S. Food and Drug Administration (FDA) cleared for marketing a test that uses molecular biology to quickly detect the presence of viral meningitis.
A new study sheds additional light on how erectile dysfunction (ED) interacts with diabetes. The study is another step in uncovering the link between the two disorders, and may lead to improved efficacy in treatments.
The three most common forms of acute viral hepatitis in the United States ? hepatitis A, B and C ? declined dramatically between 1995 and 2005, with hepatitis A and B at the lowest levels ever recorded since the government began collecting surveillance data more than 40 years ago, according to the Centers for Disease Control and Prevention (CDC). Hepatitis B and C are diseases that can lead to liver cancer and death.
Two researchers from the University Hospital and the Center for Applied Medical Research (CIMA) from the University of Navarra have published an article in Nature Cancer Reviews.
New evidence suggests that the risk of HIV transmission may be highest in the early stages of infection. According to a study published in the April 1 issue of the Journal of Infectious Diseases, now available online, early infection accounted for nearly half of all transmission occurrences in an HIV-infected population in the province of Quebec, Canada.
Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure.
GlaxoSmithKline (GSK) announces clinical trial data from two new studies, which show, for the first time, that GSK?s candidate pre-pandemic split antigen H5N1 vaccine, formulated with GSK?s proprietary adjuvant system, provides a substantial level of cross-immunity against a ?drifted? (diverse) strain of H5N1.
At this week’s major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an entirely new way. A 24 week analysis showed that approximately twice as many patients receiving maraviroc with an optimized background regimen achieved undetectable virus in the blood than if an optimized regimen was given alone.
Results from two ongoing Phase III studies of ISENTRESS? (raltegravir), an investigational oral integrase inhibitor, demonstrated significantly greater antiretroviral activity of ISENTRESS when used in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV-infected patients who had failed antiretroviral therapies (ARTs), and who had HIV virus resistant to at least one drug in each of the three available classes of oral ARTs.